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Thrombotic microangiopathy (TMA) is a rare complication of gemcitabine treat-
ment. A 55-year-old man with a history of urothelial cancer underwent right ure-
teronephrectomy and palliative chemotherapy. The patient presented with dyspnea,
generalized edema with foamy urine, and new-onset hypertension with acute
kidney injury (AKI). Although AKI with oliguria was evident, thrombocytopenia and
hemolytic anemia were not overt. To determine the cause of rapidly progressive
azotemia, kidney biopsy was performed despite a single kidney and revealed
chronic TMA. Microangiopathic hemolytic anemia and thrombocytopenia devel-
oped after renal biopsy. Diagnosed as gemcitabine-induced TMA, gemcitabine
cessation and active treatment including steroids, plasmapheresis, and rituximab
were carried out, but the patient׳s condition progressed to a dialysis-dependent
state. Gemcitabine-induced TMA is often difﬁcult to diagnose because of its vari-
able clinical course. Therefore, heightened awareness of this potentially lethal
complication of gemcitabine is essential; renal biopsy may be helpful.
Copyright © 2015. The Korean Society of Nephrology. Published by Elsevier Ltd. This
is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Gemcitabine is a nucleoside analogue of cytarabine, ﬁrst
approved by the US Food and Drug Administration in 1996. Its
use has increased because of relatively mild complications.
Currently, in combinationwith other chemotherapeutic agents,
gemcitabine is included among ﬁrst-line treatments in some
adjuvant and palliative settings for nonesmall cell lung,
ovarian, breast, and pancreatic cancers. In urothelial tumors,
gemcitabine with cisplatin showed equal efﬁcacy and lessternal Medicine, Seoul
Jongno-gu, Seoul 03080,
iety of Nephrology. Published
y-nc-nd/4.0/).toxicity in elderly patients and currently, is a ﬁrst-line regimen
in advanced stages.
Thrombocytopenia and anemia are the most common
complications of gemcitabine-induced myelosuppression. Mild
proteinuria, microscopic hematuria, and elevated levels of
blood urea nitrogen (BUN) and creatinine (Cr) can occur after
gemcitabine treatment but are rarely of clinical signiﬁcance.
Nevertheless, gemcitabine-induced thrombotic micro-
angiopathy (TMA) has been reported in a few cases and it can
lead to persistent kidney failure with poor prognosis. The ﬁrst
case was reported in 1994; the currently known incidence of
gemcitabine-induced TMA is 0.015e1.4% [1,2]. The combination
therapies with other chemotherapeutic agents including car-
boplatin, cisplatin, vinorelbine, tegafur, and docetaxel may in-
crease the risk of TMA as discussed in previous studies [3,4].by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
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occurred in patients with urothelial cancer, but none of these
included a nephrectomy case [5e7]. We report the case of
gemcitabine-induced TMA in a patient with a single-kidney
urothelial cancer, who eventually needed kidney biopsy for
diagnosis.
Case report
A 55-year-old man, who had undergone palliative chemo-
therapy for urothelial carcinoma, was referred to nephrology
for dyspnea and generalized edema for a month. One year
previously, he was diagnosed with urothelial carcinoma when
he visited a clinic on account of right ﬂank pain. He received
one cycle of neoadjuvant chemotherapy with gemcitabine/
cisplatin but did not continue because of elevation of the liver
enzyme level. After the neoadjuvant chemotherapy, thrombo-
cytopenia developed (92,000/mm3), but the thrombocyte
count returned to a normal level within 1 week. The ﬁnal
pathologic staging after right nephroureterectomy was T3Nx.
Pathologic ﬁndings of the nonetumor-involved kidney tissue
showed a normal glomerulus without signiﬁcant tubular
damage. At the time of surgery, his renal function was within
the normal range. BUN and serum Cr (sCr) levels were 15 mg/dL
and 1.2 mg/dL, respectively. Three months after surgery, mul-
tiple lymph node metastases were found on positron emission
tomography, after completion of four cycles of palliative gem-
citabine/cisplatin over 3 months. In each cycle, 35 mg/m2 of
cisplatin and 1,500 mg/m2 of gemcitabine were injected. Cu-
mulative doses of cisplatin and gemcitabine were 294 mg and
18,354 mg, respectively, including neoadjuvant and palliative
chemotherapy.
The patient was hospitalized with dyspnea on exertion and
generalized edema, developing during the ﬁnal month of
chemotherapy. He had gained 10 kg in 1 month and also re-
ported foamy urine. He did not have a history of hypertension,
but his blood pressure was elevated up to 164/110 mmHg. Daily
urine output had decreased to less than 500 mL/day, and lowerFigure 1. Peripheral blood smear. The arrows indicate schistocytes.extremity pitting edema was prominent. The white blood cell
count was 4,303/mm3, the hemoglobin level was 9.1 g/dL, and
the platelet count was 133,000/mm3. BUN and sCr levels were
elevated to 42 mg/dL and 3.4 mg/dL, respectively. Serologic test
results were within the normal range, except for ﬂuorescent
antinuclear antibody titer positive at 1:40. Urinalysis showed
2þ albuminuria and microscopic hematuria. The spot urine
protein-to-Cr ratio (g/g) was 15.32, and the albumin-to-Cr ratio
(g/g) was 9.375. Shifting bilateral pleural effusions were found
on chest radiography. On renal ultrasonography and abdominal
computed tomography, the single left kidney measured
10.3 cm, without evidence of hydronephrosis. Interval decrease
of multiple lymph nodemetastases was seen. On hospital day 3,
hemodialysis was started because of worsening dyspnea and
progressive azotemia. To differentiate the cause of rapidly
progressive renal failure, we performed a kidney biopsy despite
his single kidney.
After the biopsy, anemia and thrombocytopenia worsened,
with a hemoglobin level of 7.9 mg/dL and a platelet count of
98,000/mm3. Additional laboratory results were compatible
with microangiopathic hemolytic anemia (MAHA), including
decreased haptoglobin (8 mg/dL) and elevated plasma hemo-
globin (10.5 mg/dL) levels, increased lactic acid dehydrogenase
(533 IU/L) levels, and schistocytes on peripheral blood smears
(Fig. 1). Ultimately, we demonstrated chronic TMA involvement
of the kidney with endothelial hypercellularity and a tram-
track appearance, combined with acute tubulitis from the
kidney biopsy (Fig. 2).
The patient underwent steroid and rituximab therapy, with
16 sessions of plasmapheresis; however, his kidney failure did
not recover, and he progressed to a dialysis-dependent state.
Bone marrow biopsy was performed to check for an occult
cause of refractory TMA, even after the intensive treatments,
but did not show any abnormality. After 5 weeks of the treat-
ments, thrombocytopenia began to recover, but urothelial car-
cinoma metastases progressed, and the patient is currently on
second-line palliative chemotherapy with weekly taxol. The
patient׳s clinical course and laboratory parameters are shown
in Fig. 3.
Discussion
TMA is a spectrum of diseases that includes thrombotic
thrombocytopenic purpura and hemolytic uremic syndrome,
characterized by glomerular microvascular endothelial injury.
Anemia and thrombocytopenia occur as a result of MAHA, and
other organs are often injured. In the kidney, TMA appears as
endocapillary cell swelling, ﬁbrin thrombi, platelet plugs,
arterial intimal ﬁbrosis, and membranoproliferation. Many
chemotherapeutic agents, including mitomycin, bleomycin,
cisplatin, and 5-ﬂuorouracil, can induce TMA, but the precise
pathophysiology is unknown. Since its initial use, a few cases of
gemcitabine-induced TMA have been reported.
The incidence of gemcitabine-induced TMA varies between
0.015% (based on clinical trials) and 0.41% (from a single-center
study) [1,2]. Gemcitabine-induced TMA can occur at a cumula-
tive dose of 2,450 mg/m2 and within 3 months after the ﬁrst
chemotherapy cycle, but the risk of occurrence seems to increase
when the cumulative dose approaches 20,000 mg/m2 and more
than 18 doses are administered [8]. Although kidney biopsy is
necessary for conﬁrmation, clinical manifestations, such as
MAHA and thrombocytopenia with acute kidney injury (AKI),
Figure 2. Light microscopy of renal biopsy. The arrows indicate endothelial hypercellularity with a tram-track appearance. Stains used were hematoxylin
and eosin (A) and methenamine silver (B), with 400 magniﬁcation for both.
Figure 3. Clinical course and laboratory data. BUN, blood urea nitrogen.
Ryu et al / Gemcitabine-induced thrombotic microangiopathy 239are sufﬁcient for diagnosis inmost cases. New or exacerbation of
hypertension and proteinuria may appear before clinical mani-
festations. Neurologic and respiratory symptoms are often
associated with gemcitabine-induced TMA [9]. Discontinuation
of gemcitabine and plasmapheresis with steroids is the primary
therapy for TMA. In some patients, dialysis is needed for AKI.
Recently, rituximab treatment showed beneﬁt in cases re-
fractory to plasmapheresis and steroid therapy [9,10].
For diagnosis of chemotherapy-induced TMA, various fac-
tors need to be considered when thrombocytopenia with AKI
occurs during palliative treatment. Thrombocytopenia and
anemia can occur with myelosuppression, and chemotherapy-induced tubulopathy and microangiopathy caused by dissem-
inated cancer can induce AKI. Early diagnosis and proper
management are important to improve prognosis and enable
further cancer treatment, but differential diagnosis is often
difﬁcult based on clinical manifestations. In addition, the vari-
able time course of gemcitabine-induced TMA presentation
makes diagnosis more complicated.
In our case, gemcitabine-induced TMA presented acutely on a
chronic course. From the patient׳s history, foamy urine with
dyspnea and generalized edema appeared at least 1 month
before admission, which was 7 months after the initial gemci-
tabine dose, and 3 months after the start of palliative therapy.
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symptoms. Although AKI was overt, with oliguria at the time of
the admission, thrombocytopenia and MAHA were not evident.
For correct diagnosis and management, kidney biopsy was
inevitable, despite the single kidney. Kidney pathology showed
chronic TMA features. In this patient, thrombocytopenia and
anemia recovered slowly, eventually requiring maintenance
dialysis, even after active treatments including plasmapheresis
and steroids. During the treatment of TMA, the cancer pro-
gressed, which suggested a poor prognosis.
This case highlights the importance of following blood
pressure and urinalysis for new-onset hypertension and pro-
teinuria for early diagnosis, when treating with gemcitabine. In
patients with urothelial cancer, urinalysis with Cr testing
should be performed routinely, with the caveat that various
conditions can affect the result, including postoperative
changes, tumor progression, and chemotherapy complications,
as in this case. A high index of suspicion is required for early
diagnosis, and biochemical tests associated with hemolysis
should be considered.
In conclusion, we report a case of chronic TMA induced by
gemcitabine that required kidney biopsy for diagnosis in a
patient with a single kidney. Usually, TMA can be differentially
diagnosed from MAHA features, thrombocytopenia, and other
clinical manifestations, but sometimes, kidney biopsy is even-
tually needed to differentiate other causes. We should be aware
of the importance of careful monitoring in renal function and
be suspicious about TMA in patients with urothelial cancer with
palliative gemcitabine treatments as in this case.Conﬂicts of interest
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